INO - Inovio Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.34
-0.52 (-3.50%)
At close: 4:00PM EDT

14.33 -0.01 (-0.07%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close14.86
Open14.52
Bid14.22 x 800
Ask14.25 x 1800
Day's Range13.76 - 14.52
52 Week Range1.92 - 19.36
Volume15,648,501
Avg. Volume43,015,898
Market Cap2.267B
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-1.16
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Inovio Shares Rose 22.6% in May
    Motley Fool

    Why Inovio Shares Rose 22.6% in May

    Inovio Pharmaceuticals (NASDAQ: INO) shares climbed 22.6% in May, according to data from S&P Global Market Intelligence, as investors cheered the rapid development of its coronavirus vaccine and as the company published positive preclinical data. Inovio in late April said it completed enrollment of 40 healthy volunteers in a phase 1 trial for its coronavirus vaccine and said it expects preliminary data in late June. The company last month announced the publication of preclinical data showing strong neutralizing antibody and T-cell immune responses in animal models.

  • Inovio Analyst Watches Coronavirus Play 'From The Sidelines'
    Benzinga

    Inovio Analyst Watches Coronavirus Play 'From The Sidelines'

    Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) is not an outright buy at this point in time, according to an analyst at Piper Sandler.The Inovio Analyst Christopher Raymond maintained a Neutral rating on Inovio shares with an $8 price target. The Inovio Thesis The 12-month overall survival data Inovio presented for its DNA cancer vaccine INO-5401 in glioblastoma multiforme -- a deadly form of brain cancer -- at the ASCO made the benefit less clear, Raymond said in a Monday note. (See his track record here.) The vaccine is being studied in a Phase 2 single-arm study in newly diagnosed GBM patients following gross total resection and in combo with radiotherapy, temozolomide and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo, he said. "While the data have demonstrated that a subset of patients had a T cell response to treatment, there is still uncertainty over INO-5401's individual therapeutic benefit." Longer-term and randomized data for the vaccine would help Piper Sandler feel more confident in the program, Raymond said.An overall survival update due later this year is a key catalyst for the program, the analyst said. Given the uncertainty, he said INO-5401 remains an unmodeled opportunity at this point.Piper Sandler sees several upcoming catalysts for Inovio, including first-in-human data from INO-4800 due later this month and an update on potential funding for the program to support further development."However, given the ongoing volatility surrounding this name over COVID-19 efforts, we prefer to watch this story play out from the sidelines," Raymond said. INO Price Action At last check, Inovio shares were down 5.85% at $13.99. Related Links:The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Latest Ratings for INO DateFirmActionFromTo May 2020BenchmarkInitiates Coverage OnBuy Apr 2020StifelMaintainsBuy Apr 2020HC Wainwright & Co.ReiteratesBuy View More Analyst Ratings for INO View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant * The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas * The Week Ahead In Biotech: ASCO Presentations In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?
    Motley Fool

    Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?

    The coronavirus vaccine race offers these clinical stage companies an opportunity to bring a first product to market -- if all goes well in human trials.

  • Why Moderna Stock Is Still Only Good for Speculators
    InvestorPlace

    Why Moderna Stock Is Still Only Good for Speculators

    Speculation surrounding the novel coronavirus has taken over the stock market. Hope for a cure or, better yet, a vaccine, is driving traders into frenzies. Much of the action is centered around Moderna (NASDAQ:MRNA) and MRNA stock.Source: Shutterstock While the company had just $8.3 million in revenue for the March quarter, it entered trade May 29 with a market cap of $20.6 billion.MRNA stock has been on fire for months. In February, the shares cost $18. It was the release of Phase 1 data earlier this month that sent traders into a frenzy. That showed, as expected, that antibodies against the virus were produced in test subjects. The company also said it was rapidly scaling up production.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTraders who had been buying Moderna rumors sold the news. The shares have since fallen from the mid-80's to the mid-50's. Why Moderna?Nothing has gone wrong, from a scientific standpoint. It's just that there are no guarantees Moderna has the winning lottery ticket.There are now 28 different vaccines being researched around the world, with eight in some type of clinical trial. There are vaccines being tested in England, in China and in Australia. Two other publicly traded U.S. companies, Pfizer (NYSE:PFE) and Inovio Pharmaceuticals (NASDAQ:INO), have Covid-19 vaccine candidates in trial. Novavax (NASDAQ:NVAX), Johnson & Johnson (NYSE:JNJ), and Altimmune (NASDAQ:ALT) are all doing pre-clinical work. So are Merck (NYSE:MRK), GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY). * 7 Red-Hot Vaccine Stocks Racing to Develop a Coronavirus Cure Moderna just got there first, with the most publicity. It announced funding on Jan. 23. It's working with the National Institute of Allergy and Infectious Diseases (NIAID), headed by the now-famous Dr. Anthony Fauci. It won an invitation to the White House to talk about its candidate, mRNA-1273. Why Not Moderna?The problem is that vaccines are hard. It's not enough to create antibodies against the disease. A vaccine must stop the spread safely across millions or (in this case) billions of doses.Safety is one issue. Four of the 45 people tested in the Phase 1 study developed reactions to the Moderna vaccine. One 29-year old tweeted that he got a 103 degree fever. He said his dose was 10 times what other patients got, and he didn't go to a hospital in fear of triggering "anti-vax" people.Efficacy is a second issue. Only eight of the subjects produced binding antibodies. Only four were sampled for neutralizing antibodies. The level of T-Cell generation, a measure of how the body is attacking the virus, wasn't mentioned.Moderna's own actions are also an issue. The company announced a $1 billion secondary offering right after its Phase 1 results came out. Some executives sold shares within days. Moderna is moving directly into a Phase 3 study, and mass production, while its Phase 1 is still being evaluated.All these actions have raised suspicions among people who know both science and market valuations. The Bottom Line on MRNA StockThis is my fourth piece on Moderna in six months.I was very positive about MRNA stock when it came public in December. Its methodology, using Messenger RNA, impressed me. In April, I called Moderna "the greatest coronavirus speculation." The problem is success against Covid-19 is now built-into the stock price. Success is far from guaranteed. There are many other horses in this race. It's far from clear how profitable this vaccine will be.It's possible mRNA-1273 could be the start of a business that goes on for decades. It's possible that mRNA-1273 proves Moderna's methodology and it becomes one of the world's great companies. It's also possible that mRNA-1273 fails in Phase 3.There are too many known unknowns for me to recommend investing in MRNA stock at its present price. But you're welcome to speculate.Dana Blankenhorn has been a financial journalist since 1978. His latest book is Technology's Big Bang: Yesterday, Today and Tomorrow with Moore's Law, essays on technology available at the Amazon Kindle store. Follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in JNJ. More From InvestorPlace * Top Stock Picker Reveals His Next 1,000% Winner * The Huge Story for 2020 & Beyond That You Aren't Hearing About * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * The 1 Stock All Retirees Must Own The post Why Moderna Stock Is Still Only Good for Speculators appeared first on InvestorPlace.

  • Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Inovio Pharmaceuticals, Inc. (INO)
    Business Wire

    Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Inovio Pharmaceuticals, Inc. (INO)

    Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.

  • Investopedia

    Novavax and Merck Fuel COVID-19 Vaccine Hopes

    Novavax has begun human trials, and Merck has joined the race with the acquisition of Themis and collaboration with non-profit IAVI.

  • INOVIO to Host Webinar "DNA Medicines: From COVID-19 to Cancer"
    PR Newswire

    INOVIO to Host Webinar "DNA Medicines: From COVID-19 to Cancer"

    INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases, cancer, and diseases associated with HPV, today announced it will hold a webinar event on June 1 from 10 AM to noon EDT to detail its proprietary DNA medicines technology and provide updates on INO-4800, its DNA vaccine in Phase 1 clinical development for COVID-19, and INO-5401, its DNA immunotherapy designed to treat glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer. Preclinical data on INO-4800 demonstrating robust neutralizing antibody and T cell immune responses was published in the peer-reviewed journal Nature Communications on May 20, 2020. Data demonstrating 85% of newly diagnosed glioblastoma patients were alive 12 months following treatment with INO-5401, in combination with INO-9012 and PD-1 inhibitor Libtayo® (cemiplimab), will be featured at an oral poster presentation at the ASCO 2020 Virtual Scientific Program, May 29-31, 2020.

  • An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race
    Yahoo Finance

    An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race

    Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.

  • Inovio Can Climb Higher, Says Top Analyst
    TipRanks

    Inovio Can Climb Higher, Says Top Analyst

    The race to develop a vaccine against COVID-19 is charging full speed ahead. Yesterday, Inovio Pharmaceuticals (INO) released promising preclinical data for the biotech’s COVID-19 DNA vaccine candidate, INO-4800. Investors have high hopes for the vaccine maker and have sent the stock soaring by over 332% so far this year. The results, published in Nature Communications, showed INO-4800 elicited strong binding and neutralizing antibody responses in addition to high-level T cell responses in mice and guinea pigs. INO-4800 targets the major antigen spike protein of the SARS-CoV-2 virus, which causes COVID-19, and is currently in a Phase 1 trial. 40 healthy volunteers are taking part, with interim data expected in June. With data in hand, Inovio will approach the FDA for authorization to move forward with a Phase 2/3 trial, which it hopes to initiate in July or August. The company expects to recruit 2,000 frontline healthcare workers for the Phase 2/3 study. “We believe data from this randomized trial, if positive, could allow the company to file for emergency regulatory approval for INO-4800,” said H.C. Wainwright’s Ram Selvaraju. Additionally, Inovio will examine the vaccine in larger animals including rabbits and monkeys. The company will conduct "challenge" studies, which involve giving the virus to an animal and then seeing if the vaccine prevents the infection. “In our view, these animal data bode well for the upcoming data from multiple animal challenge studies and data readout from the ongoing Phase 1 study in June,” Selvaraju added. It should come as no surprise, then, that the 5-star analyst reiterated a Buy rating on Inovio, accompanied by a $17 price target. There’s upside of 22% in the cards, should the target be met over the next 12 months. (To watch Selvaraju’s track record, click here) Over the last three months, 8 analysts have thrown the hat in with a view on the vaccine maker’s prospects, with 5 recommending Buy and 3 saying Hold. This makes the consensus rating a Moderate Buy. Overall, the Street sees upside potential of 18% ahead, as the average price target comes in at $16.57. (See Inovio stock analysis on TipRanks)

  • Fmr. CDC Official: 'we’re not cutting any corners' on COVID-19 vaccine development
    Yahoo Finance Video

    Fmr. CDC Official: 'we’re not cutting any corners' on COVID-19 vaccine development

    Vanderbilt University School of Medicine,Professor of Medicine in the Division of Infectious Diseases Dr. William Schaffner joins Yahoo Finance’s Seana Smith to discuss the coronavirus, as a quarter of Americans say they are nervous about a vaccine, according to a new Reuters/Ipsos poll.

  • Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline
    Benzinga

    Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline

    A day after short seller Citron Research slammed Inovio Pharmaceuticals Inc (NASDAQ: INO), sell-side analysts lined up behind the company. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.The Inovio Analysts Benchmark analyst Aydin Huseynov initiated shares of Inovio with a Buy rating and $28 price target. H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $17 price target.Inovio Shares To Benefit From Likelihood of Financing For COVID Vaccine, Benchmark Says Inovio's SARS-CoV-2 vaccine candidate INO-4800 has a meaningful chance of progressing to Phase 2/3 in the July-August timeframe and securing the necessary financing from the government or nonprofits, Benchmark analyst Huseynov said in a note.Noting that Inovio has a pipeline of vaccine candidates for various infectious diseases such as HIV, Ebola, MERS and Zika, the analyst said the company will get sufficient financial support for every promising vaccine candidate, including INO-4800."Also, Inovio's DNA plasmid platform has commercially and clinically attractive HPV-targeting and immuno-oncology drug candidates that may drive INO's shareholder value longer term." The higher probability of Inovio securing external non-dilutive financing to move INO-4800 further into the clinic is likely to help its share price, Huseynov said.The analyst also noted that the company has promising late-stage oncology assets, VGX-3100 and INO-5401, with potential launches in 2023 and combined risk-unadjusted peak 2035 sales of $1.4 billion.See also: AstraZeneca Receives Over B In BARDA Funding For Coronavirus Vaccine Preclinical Data Bode Well For Phase 1 Data Due In June, HC Wainwright Says Preclinical studies showed that vaccination with INO-4800 generated binding and neutralizing antibodies as well as T cell responses in mice and guinea pigs, H.C. Wainwright analyst Selvaraju said.The fact that researchers were able to demonstrate neutralizing activity of the vaccine using three separate neutralization assays is remarkable, the analyst said. Additionally, these antibodies were detected in the lungs of the vaccinated animals, and high levels of Spike-specific T cell responses were observed, he said. "In our view, these animal data bode well for the upcoming data from multiple animal challenge studies and data readout from the ongoing Phase 1 study in June." INO Price Action Inovio shares were trading down 9.86% at $14.23 at the time of publication Thursday.Related Link: The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive Latest Ratings for INO DateFirmActionFromTo May 2020BenchmarkInitiates Coverage OnBuy Apr 2020StifelMaintainsBuy Apr 2020HC Wainwright & Co.ReiteratesBuy View More Analyst Ratings for INO View the Latest Analyst Ratings See more from Benzinga * Inovio Publishes Positive Animal Testing Data For Coronavirus DNA Vaccine * Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Citron Questions Inovio's 'Robust' Preclinical Coronavirus Vaccine Announcement, Sees 90% Downside Ahead
    Benzinga

    Citron Questions Inovio's 'Robust' Preclinical Coronavirus Vaccine Announcement, Sees 90% Downside Ahead

    Inovio Pharmaceuticals Inc (NASDAQ: INO) said Wednesday that positive preclinical data for its DNA vaccine for the SARS-CoV-2 has been published in a peer-reviewed journal, sending its shares higher.Inovio's Preclinical Data News Stale? Following the announcement, short seller Citron Research came down heavily on the company, stating in its report that the announcement is not a fresh one and calling for the SEC to halt trading in the stock. "We immediately began preclinical testing and small-scale manufacture and have already shared robust preclinical data with our public and private partners," Inovio's CEO Dr. Joseph Kim said in a March 3 release.Citron Sees Tall But Empty Claims From Inovio Citron also said the situation is deja vu. Inovio has been in the habit of sharing press releases highlighting positive animal testing data for "every disease it researches" without producing a single commercial product in 40 years, Citron said in the report, lining up Inovio's previous releases as evidence for its claim."Simply put, Inovio is nothing but over 40 years of 'robust' data without a single product to market," Citron said.Benzinga has contacted Inovio for comment on the Citron report. About 90% Downside Likely For Inovio, Short Seller Says In a tweet, Citron assigned a $2 price target for the company, which represents about 86% downside from Tuesday's closing price.> $INO Company should be halted as they have no shame in this time of crisis. Read Citron to see how $INO issued "robust preclinical" data in EVERY situation that has resulted in 0 products to market. Company has become a full stock promotion. Tgt price $2> > -- Citron Research (@CitronResearch) May 20, 2020Inovio shares were trading 8.73% higher at $15.83 at the time of publication Wednesday. Related Links: The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test See more from Benzinga * Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand * Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Coronavirus update: Global case tally at 4.9 million as Trump considers travel ban on Brazil after big jump in death toll
    MarketWatch

    Coronavirus update: Global case tally at 4.9 million as Trump considers travel ban on Brazil after big jump in death toll

    The number of global cases of the coronavirus that causes COVID-19 rose to 4.9 million on Wednesday and Brazil suffered its worst fatalities since the start of the outbreak, prompting President Donald Trump to say he may bar entry to flights from Brazil.

  • Barrons.com

    Another Biotech Stock Gets a Lift From Encouraging, but Early, Vaccine Data

    Inovio, like Moderna, is conducting a Phase 1 human trial of its vaccine, with 40 volunteers enrolled. It plans to report initial results on safety and immune responses in that study in late June.

  • Inovio Pops Almost 10% on ‘Positive’ Preclinical Results For Its Covid-19 Vaccine
    SmarterAnalyst

    Inovio Pops Almost 10% on ‘Positive’ Preclinical Results For Its Covid-19 Vaccine

    Inovio Pharmaceuticals (INO) surged almost 10% after the company said that preclinical study data results of its potential vaccine candidate showed “robust” neutralizing antibody and T cell immune responses against coronavirus.Shares rose 9.5% to $15.94 in midday U.S. trading. The value of the stock has this year gone up five-fold with investors excited about Inovio’s potential Covid-19 vaccine INO-4800. The vaccine drug candidate targets the major antigen Spike protein of SARS-CoV-2 virus, which causes Covid-19 disease."These positive preclinical results from our Covid-19 DNA vaccine not only highlight the potency of our DNA medicines platform, but also build on our previously reported positive Phase 1/2a data from our vaccine against the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralization from a similarly designed vaccine INO-4700,” said Kate Broderick, Inovio's Senior VP of R&D. “The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials."The study found that vaccination with INO-4800 generated robust binding and neutralizing antibody as well as T cell responses in mice and guinea pigs. What’s more Inovio now expects in June to receive preliminary safety and immune responses data from Phase 1 clinical trial.“We are planning to utilize these positive preclinical results along with our upcoming animal challenge data and safety and immune responses data from our Phase 1 studies to support rapidly advancing this summer to a large, randomized Phase 2/3 clinical trial,” said Dr. J. Joseph Kim, Inovio’s President & CEO.Inovio is currently preparing to initiate a larger Phase 2 vaccine trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred. Phase 2/3 trial is now planned to start in July or August pending regulatory approval.Five-star analyst Jason McCarthy at Maxim Group this month raised his price target on the stock to $18 from $12 and maintained a Buy rating.“Inovio and its deep pipeline of DNA vaccines for infectious diseases, including other coronaviruses, has demonstrated safety and induced robust immune responses, more than any in the space, in our view,” McCarthy wrote in a note to investors. “Yet, from a valuation perspective INO lags its nucleic-acid vaccine peers MRNA and BNTX.The Street has a cautiously optimistic outlook on Inovio, with a Moderate Buy consensus based on 4 Buys and 3 Holds. As share prices have skyrocketed so quickly, the $14.14 average analyst price target now indicates more than 10% downside potential. (See Inovio stock analysis on TipRanks).Related News: Bluebird Prices New Shares At $55, Seeks To Raise $500 Million Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data AstraZeneca-Merck Lynparza Prostate Cancer Treatment Gets FDA Approval More recent articles from Smarter Analyst: * Boeing Cuts 6,770 Jobs In U.S.; CFRA Upgrades Stock To Buy   * Google Faces Arizona Lawsuit Over ‘Unfair’ Location Data Storing * Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses; Top Analyst Ramps Up PT To $61 * Hertz Sinks 11% After-Hours As Carl Icahn Sells Stake At $1.8B Loss

  • Benzinga

    Price Over Earnings Overview: Inovio Pharmaceuticals

    In the current session, Inovio Pharmaceuticals Inc. (NASDAQ: INO) is trading at $16.17, after a 11% rise. Over the past month, the stock increased by 38.12%, and in the past year, by 397.66%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 16.48%.The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Inovio Pharmaceuticals has a better P/E ratio of 0.0 than the aggregate P/E ratio of 0.0 of the biotechnology industry. Ideally, one might believe that Inovio Pharmaceuticals might perform better in the future than it's industry group, but it's probable that the stock is overvalued.There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * 16 Healthcare Stocks Moving In Wednesday's Pre-Market Session * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Inovio Publishes Positive Animal Testing Data For Coronavirus DNA Vaccine
    Benzinga

    Inovio Publishes Positive Animal Testing Data For Coronavirus DNA Vaccine

    With the Street and experts divided on rival Moderna Inc's (NASDAQ: MRNA) recently released interim Phase 1 readout, Inovio Pharmaceuticals Inc (NASDAQ: INO) released positive preclinical data for its SARS-CoV-2 vaccine candidate INO-4800.What Happened?Pennsylvania-based Inovio announced publication of data from animal testing of INO-4800 in the peer-reviewed journal "Nature Communications" showing robust neutralizing antibody and T-cell immune responses against the coronavirus mice and guinea pigs.The article was authored by Inovio scientists and collaborators from the Wistart Institute, the University of Texas, Public Health England, Fudan University and Advaccine."These positive preclinical results from our COVID-19 DNA vaccine not only highlight the potency of our DNA medicines platform, but also build on our previously reported positive Phase 1/2a data from our vaccine against the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralization from a similarly designed vaccine INO-4700," said Dr. Kate Broderick, SVP of R&D and Team Lead for COVID-19 vaccine at Inovio.Data also showed antibodies were detected in the lungs of the vaccinated animals, which could be important in providing protection from SARS-CoV-2. Additionally, high levels of Spike-specific T-cell responses were observed with INO-4800 vaccination, underlining its importance in mediating protection from the virus infection.Why It MattersWith the COVID-19 pandemic bringing the world to a standstill, biopharma companies and institutions have plunged headlong into developing a treatment or vaccine to counter the virus.Inovio was touted to be one of the frontrunners for a vaccine against the virus. Moderna reported Monday positive interim Phase 1 data for its mRNA vaccine candidate mRNA-1273. STAT News reported, citing experts, data from eight subjects is not adequate to authenticate the efficacy and safety results released by the company.What's Next?Inovio said these positive preclinical results along with its upcoming animal challenge data, and safety and immune responses data from its Phase 1 studies support rapid advancement of the INO-4800 this summer to a large, randomized Phase 2/3 clinical trial.In pre-market trading Wednesday, Inovio shares were higher by 14.08% to $16.61.Related Links:A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan StanleySee more from Benzinga * Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand * Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • U.S. Stocks Set To Open Higher On Renewed Optimism
    FX Empire

    U.S. Stocks Set To Open Higher On Renewed Optimism

    S&P; 500 futures are up more than 1% in premarket trading as Inovio Pharmaceuticals reports promising results for its COVID-19 vaccine.

  • MarketWatch

    Inovio's stock gains on early data testing its COVID-19 vaccine in animals

    Shares of Inovio gained 22.8% in premarket trading on Wednesday after the company said its COVID-19 vaccine candidate demonstrated neutralizing antibodies in animals. The data, published in Nature Communications, is from a preclinical study, meaning it does not include information about how the investigational vaccine reacts in humans but in mice and guinea pigs. Inovio is currently conducting a Phase 1 clinical trial testing the DNA vaccine candidate in people; early data from that study is expected to be announced in June. "The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials," Dr. Kate Broderick, Inovio's team lead for COVID-19 vaccine development, said in a news release. There are no proven vaccines that prevent against infections with COVID-19. Moderna Inc. announced early positive results from its Phase I trial testing a vaccine candidate in people on Monday. Inovio's stock is up 341.2% year-to-date, while the S&P 500 is down 9.5%.

  • Inovio says COVID-19 vaccine produces antibodies in mice, guinea pigs
    Reuters

    Inovio says COVID-19 vaccine produces antibodies in mice, guinea pigs

    "We saw antibody responses that do many of the things we would want to see in an eventual vaccine," said Dr. David Weiner, director of the vaccine and immunotherapy center at the Wistar Institute, which has collaborated with Inovio. There are currently no approved treatments or vaccines for COVID-19, the disease caused by the new coronavirus, with governments, drugmakers and researchers working on around 100 vaccine programs. Many other drugmakers including Moderna Inc, Pfizer Inc, Johnson & Johnson, Sanofi and AstraZeneca Plc are also in various stages of vaccine development.

  • INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models
    PR Newswire

    INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models

    INOVIO (NASDAQ:INO) today announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2. The study was published in the peer-reviewed journal Nature Communications titled, "Immunogenicity of a DNA vaccine candidate for COVID-19" by INOVIO scientists and collaborators from The Wistar Institute, the University of Texas, Public Health England, Fudan University, and Advaccine.

  • Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'
    Yahoo Finance Video

    Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'

    Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.